The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .
Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women.
OBJECTIVES This study was carried out to assess the effect of topical and rogen replacement therapy on body weight , body composition and fat distribution in postmenopausal women . METHODS 39 healthy postmenopausal women ( 51.4 + /- 2.24 years ) , with increasing body weight , were prospect ively studied for 6 months . Body composition ( fat mass , kg , % ) was measured by means of dual-energy X-ray absorptiometry ( DXA ) . Hormonal and lipid parameters were also measured . Subjects were divided into two groups . An and rogen gel ( group A ) or placebo gel ( group P ) was topically administered to the abdominal and gluteo-femoral regions . DXA was performed before commencement of topical treatment and after 6 months . RESULTS A highly significant total body weight reduction was found in group A ( 68.0 + /- 13.1 to 65.4 + /- 11.8 kg ) . Abdominal fat ( 37.3 + /- 11.2 to 35.1 + /- 9.7 % ) , gluteo-femoral fat ( 46.3 + /- 6.6 to 45.4 + /- 7.7 % ) , total body fat ( 38.2 + /- 7.9 to 36.1 + /- 8.6 % ) and BMI ( 24.8 + /- 4.3 to 23.7 + /- 3.8 ) were also found to have decreased significantly in this group . No significant reduction in body weight ( kg ) and body fat ( % ) could be measured in the placebo group . No influence on lipid parameters was found although total testosterone increased significantly in group A ( 0.29 + /- 0.24 to 0.72 + /- 0.17 ng/ml ) . CONCLUSIONS Topically applied and rogen is capable of reducing abdominal fat accumulations as well as total body weight in postmenopausal women with unexplained weight gain . In contrast to systemic and rogen application , topical administration has no effect on the lipid profile . Gluteal fat , however , is less effectively influenced by and rogens
The pooled estimate from the studies suggested that the addition of testosterone to HT regimens improved sexual function scores for postmenopausal women .
A significant adverse effect was a decrease in high-density lipoprotein ( HDL ) cholesterol levels .
However , there is evidence that adding testosterone to HT has a beneficial effect on sexual function in postmenopausal women .
There was a reduction in HDL cholesterol associated with the addition of testosterone to the HT regimens .
It is , therefore , difficult to estimate the effect of testosterone on sexual function in association with any individual hormone treatment regimen
BACKGROUND : The value of adding testosterone to hormone therapy ( HT ) for the management of peri- and postmenopausal women is controversial and has not been systematic ally review ed .
OBJECTIVES : To determine the benefits and risks of testosterone therapy for peri- and postmenopausal women taking hormone therapy .